

Formulary Changes Update

The following changes to the MPC Approved Drug List (ADL) were approved by the Maryland Physicians Care Pharmacy & Therapeutics Committee. Please review these changes.

Key		
UPPER CASE = Brand Name Drugs	Lower case = Generic Drugs	QL = Quantity Limit
PA = Prior Authorizations	ST = Step Therapy	AL = Age Limit
ADL = Approved Drug List	YOA = Years of Age	DD = Discontinued Drug

January 2026

Drug Name	Therapeutic Class	Change	Effective Date	ADL Alternative (if applicable)
-----------	-------------------	--------	----------------	---------------------------------

No Formulary Changes

February 2026

Drug Name	Therapeutic Class	Change	Effective Date	ADL Alternative (if applicable)
-----------	-------------------	--------	----------------	---------------------------------

No Formulary Changes

March 2026

Drug Name	Therapeutic Class	Change	Effective Date	ADL Alternative (if applicable)
Lidocaine Patch 5%	Topical Analgesic	Remove PA requirements	03/23/2026	
Lidocaine Patch 4%	Topical Analgesic	Remove PA requirements	03/23/2026	

April 2026

Drug Name	Therapeutic Class	Change	Effective Date	ADL Alternative (if applicable)
No Formulary Changes				
May 2026				
Drug Name	Therapeutic Class	Change	Effective Date	ADL Alternative (if applicable)
Mounjaro	GIP/GLP-1 Agonist	Add to formulary w/UM requirements	05/01/2026	Ozempic, Rybelsus, Liraglutide
June 2026				
Drug Name	Therapeutic Class	Change	Effective Date	ADL Alternative (if applicable)
No Formulary Changes				
July 2026				
Drug Name	Therapeutic Class	Change	Effective Date	ADL Alternative (if applicable)
No Formulary Changes				
August 2026				
Drug Name	Therapeutic Class	Change	Effective Date	ADL Alternative (if applicable)
Umeclidinium Ellipta	Anticholinergic	Add to formulary	09/01/2026	
Xeljanz IR and ER	JAK Inhibitor	Remove from formulary	11/01/2026	Tofacitinib IR/ER
Tofacitinib IR and ER	JAK Inhibitor	Add to formulary w/PA	09/01/2026	

Effective 06.29.2026

Jardiance	SGLT2 Inhibitor	Add to formulary w/PA	10/01/2026	Dapagliflozin
Steglatro	SGLT2 Inhibitor	Remove from formulary	01/01/2027	Dapagliflozin
Segluromet	SGLT2 Inhibitor/Biguanide	Remove from formulary	01/01/2027	Dapagliflozin
Kirsty	Insulin	Add to formulary	10/01/2026	Admelog
Memantine	NMDA Receptor Antagonist	Add to formulary	09/15/2026	Galantamine, Rivastigmine
Donepezil	Acetylcholinesterase Inhibitor	Add to formulary	09/15/2026	Galantamine, Rivastigmine
September 2026				
Drug Name	Therapeutic Class	Change	Effective Date	ADL Alternative (if applicable)
No Formulary Changes				